Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 18, 2018 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ™ to be Presented at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting

- Five oral abstracts to be presented at annual meeting and subspecialty days –-24-month follow up YUTIQ data to be highlighted at a breakthrough presentation- WATERTOWN, Mass., Oct. 18, 2018 ...
October 15, 2018 06:30 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Receives FDA Approval of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg

- The first long-lasting, FDA approved micro-insert for up to three years of continuous control in chronic, non-infectious posterior segment uveitis, the third leading cause of blindness in the U.S. -...
October 01, 2018 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Announces Proceeds of $28.9 Million from Exercised Warrants

WATERTOWN, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative...
September 12, 2018 06:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Reports Fiscal 2018 Fourth Quarter & Full Year Financial Results and Highlights Recent Progress

-Substantial progress made in the Company’s accelerated transformation into a commercial entity -YUTIQ™ PDUFA date of November 5, 2018 -Commercial preparations underway for launch of DEXYCU™ in the...
September 10, 2018 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Elects Göran Ando, M.D. as Next Chairman of Board of Directors

WATERTOWN, Mass., Sept. 10, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic...
September 05, 2018 16:15 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Secures Pass-through Payment Status and Assignment of C-Code for DEXYCU™

WATERTOWN, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic...
September 05, 2018 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Announces Fiscal 2018 Fourth Quarter & Full Year Financial Results Release Date and Conference Call Information

WATERTOWN, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative...
August 28, 2018 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals to Present at Upcoming Investor Conferences

WATERTOWN, Mass., Aug. 28, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative...
August 15, 2018 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Appoints John Weet, Ph.D., as SVP, Regulatory Affairs & Quality

WATERTOWN, Mass., Aug. 15, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative...
August 03, 2018 16:05 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., Aug. 03, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative...